DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
about
Efficacy and safety of biphasic insulin aspart and biphasic insulin lispro mix in patients with type 2 diabetes: A review of the literatureInsulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesUsing insulin in type 2 diabetes: in need of a renaissance?Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysisA comparison of different statistical methods analyzing hypoglycemia data using bootstrap simulations.Comparative efficacy and safety of long-acting insulin analogs in patients with type 2 diabetes failing on oral therapy: Systemic review and meta-analysesEvidence-based clinical use of insulin premixturesPredictor variables and an equation for estimating HbA1c attainable by initiation of basal supported oral therapy.Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials.Insulin lispro protamine suspension in the treatment of patients with type 1 and type 2 diabetes mellitus: a systematic review of published data.Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetesThe DURAbility of Basal versus Lispro mix 75/25 insulin Efficacy (DURABLE) trial: comparing the durability of lispro mix 75/25 and glargineEfficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trialComparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.Diabetes: glycaemic control in type 2 (drug treatments).Role of premixed insulin analogues in the treatment of patients with type 2 diabetes mellitus: a narrative reviewStarting insulin in type 2 diabetes: real-world outcomes after the first 12 months of insulin therapy in a new zealand cohort.Initiating insulin in patients with type 2 diabetes.Practical Guidance on the Use of Premix Insulin Analogs in Initiating, Intensifying, or Switching Insulin Regimens in Type 2 DiabetesA randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes.National Variations in Comorbidities, Glycosylated Hemoglobin Reduction, and Insulin Dosage in Asian Patients with Type 2 Diabetes: The FINE-Asia Registry.Understanding heterogeneity in response to antidiabetes treatment: a post hoc analysis using SIDES, a subgroup identification algorithm.Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?Determinants of weight change in patients on basal insulin treatment: an analysis of the DIVE registry.Durability of glycemic control with insulin lispro mix 75/25 versus insulin glargine for older patients with type 2 diabetes.Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.The economic and clinical benefits of adequate insulin initiation and intensification in people with type 2 diabetes mellitus.Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.Insulin initiation in type 2 diabetes: what are the treatment regimen options and how can we best help patients feel empowered?Humalog (lispro) for type 2 diabetes.Is there evidence to support use of premixed or prandial insulin regimens in insulin-naive or previously insulin-treated type 2 diabetic patients?Achieving glycaemic targets with basal insulin in T2DM by individualizing treatment.Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus.Biphasic vs basal bolus insulin regimen in Type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.Estimate variable importance for recurrent event outcomes with an application to identify hypoglycemia risk factors.A novel approach to optimise glycaemic control in insulin users.Improvement of β-cell function after achievement of optimal glycaemic control via long-term continuous subcutaneous insulin infusion therapy in non-newly diagnosed type 2 diabetic patients with suboptimal glycaemic control.Clinical predictors of risk of hypoglycaemia during addition and titration of insulin glargine for type 2 diabetes mellitus.
P2860
Q26749095-39C5BE16-F42E-4E3A-A0F8-CC01226ABE0AQ26861313-FF1528ED-C548-4969-9BD5-4CA3D2485D78Q26863277-80A8549B-C5B9-4B91-8B2E-AE75F4586181Q28078467-5635D10D-B15F-4A37-AC9C-4C6B3527362CQ30829473-123D11E0-8945-4853-B86A-5412412C52DFQ33585766-0821FD47-27B3-4C6F-A422-A95A0E003D04Q33591271-82173A68-339C-4963-81AF-BA7194CA87EDQ33609805-D97300C7-A747-4695-874E-FD796277FA12Q33871459-253A8E58-E7B2-4DB0-897C-B80460E9FF96Q34126929-3B477734-5C8E-4C7D-8060-1F1B1256662EQ34381425-F9B0BB54-6235-4A8A-A0F7-204AB28B4578Q34506998-165DBFDC-4051-4875-BFEA-9E4DCBAADB79Q34507342-7000F1C7-2DD1-4EC6-90E7-8B454A6E3C59Q34543042-D82ED4F1-B585-44B5-B0A4-C83E9D4433F7Q34543057-F497F248-8390-4EF4-BCE2-39010F6EE9E2Q34829290-D00CD886-B113-4322-9C32-734E1D16ECB8Q34851203-5369AE4A-28B4-45E2-A7F8-7C17763ADAE3Q35217922-81431AA5-94CA-467D-893D-1C73C33B7F4EQ35894554-56BCF9ED-B16D-4825-910E-39DB9C69A1E8Q36073434-4356E2E7-90FF-4B1B-B8D3-F40B208E06FDQ36334537-23D87AD5-2691-4716-AFDA-3DCD9F4659D8Q36360049-D97D4FB7-6C37-487B-8DD2-30AC6144C2F2Q37080658-F3C365EE-462B-4975-A9CD-DD8324DAA48AQ37577153-C53AD065-A673-4A75-BB98-2E40DC3322C3Q37612059-3431D89B-DC17-4885-B3F5-F5265983A077Q37638873-7416253D-633A-47AA-A4EA-1C09EE2D1624Q37885450-9ADA0AAC-9BED-47A0-9255-DC6427709D65Q37915625-6BCC5B2D-959C-4F64-A973-56F110D34463Q37964744-81655162-9C52-4CE0-9E66-70FED5C7388BQ37972941-5D7D8B7C-3B48-4838-B65D-72913B162045Q38008005-79D45CB5-F595-4D8B-91CE-25AA7F198AD5Q38050151-98682F76-ED82-4EE2-ADA5-985FE6F3A5CDQ38123793-99450C6B-816B-4CF2-8CA8-AD3FCC5A25C3Q38188821-1E5FA8E4-9D97-4294-973F-164335B205D9Q38317168-B30BEE4C-2D3A-4E2B-B67A-F67B4EF4B8D0Q38320545-165BAE11-186E-41DB-A644-00A15F720E34Q41020338-5FE4848B-615B-4577-BB8C-386738A5D8E5Q41905403-9EC06128-0DB9-4FEE-AE62-35DFFF1969F4Q44598061-25369C2B-104E-4FBC-A6F9-5F015956E604Q46214663-52712711-94BC-4E76-B24D-2A42330C8331
P2860
DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
DURAbility of basal versus lis ...... patients with type 2 diabetes.
@en
DURAbility of basal versus lispro mix 75/25 insulin efficacy
@nl
type
label
DURAbility of basal versus lis ...... patients with type 2 diabetes.
@en
DURAbility of basal versus lispro mix 75/25 insulin efficacy
@nl
prefLabel
DURAbility of basal versus lis ...... patients with type 2 diabetes.
@en
DURAbility of basal versus lispro mix 75/25 insulin efficacy
@nl
P2093
P2860
P356
P1433
P1476
DURAbility of basal versus lis ...... patients with type 2 diabetes.
@en
P2093
Bruce H R Wolffenbuttel
Honghua H Jiang
Jamie L Scism-Bacon
Jessie L Fahrbach
Natalie K Shemonsky
Sherry A Martin
William H Herman
P2860
P304
P356
10.2337/DC08-2117
P407
P50
P577
2009-03-31T00:00:00Z